Anderson R, Qi W
Molecules. 2025; 30(4).
PMID: 40005071
PMC: 11858625.
DOI: 10.3390/molecules30040760.
Lesanavicius M, Seo D, Maurutyte G, cenas N
Int J Mol Sci. 2024; 25(10).
PMID: 38791410
PMC: 11121358.
DOI: 10.3390/ijms25105373.
Valiauga B, Bagdziunas G, Sharrock A, Ackerley D, cenas N
Int J Mol Sci. 2024; 25(8).
PMID: 38673999
PMC: 11049802.
DOI: 10.3390/ijms25084413.
Nemeikaite-ceniene A, Haberkant P, Kuciauskas D, Stein F, cenas N
Int J Mol Sci. 2023; 24(7).
PMID: 37047836
PMC: 10094930.
DOI: 10.3390/ijms24076863.
Lesanavicius M, Seo D, cenas N
Antioxidants (Basel). 2022; 11(5).
PMID: 35624864
PMC: 9137726.
DOI: 10.3390/antiox11051000.
Reactions of Recombinant Neuronal Nitric Oxide Synthase with Redox Cycling Xenobiotics: A Mechanistic Study.
Lesanavicius M, Boucher J, cenas N
Int J Mol Sci. 2022; 23(2).
PMID: 35055166
PMC: 8781745.
DOI: 10.3390/ijms23020980.
Cancer Cell Metabolism in Hypoxia: Role of HIF-1 as Key Regulator and Therapeutic Target.
Infantino V, Santarsiero A, Convertini P, Todisco S, Iacobazzi V
Int J Mol Sci. 2021; 22(11).
PMID: 34071836
PMC: 8199012.
DOI: 10.3390/ijms22115703.
Aerobic Cytotoxicity of Aromatic Oxides: The Role of NAD(P)H:Quinone Oxidoreductase (NQO1).
Nemeikaite-ceniene A, Sarlauskas J, Miseviciene L, Maroziene A, Jonusiene V, Lesanavicius M
Int J Mol Sci. 2020; 21(22).
PMID: 33228195
PMC: 7699506.
DOI: 10.3390/ijms21228754.
Reactions of Ferredoxin:NADP Oxidoreductase with Redox Cycling Xenobiotics: A Mechanistic Study.
Lesanavicius M, Aliverti A, Sarlauskas J, cenas N
Int J Mol Sci. 2020; 21(9).
PMID: 32370303
PMC: 7247349.
DOI: 10.3390/ijms21093234.
Kinetics of Flavoenzyme-Catalyzed Reduction of Tirapazamine Derivatives: Implications for Their Prooxidant Cytotoxicity.
Nemeikaite-ceniene A, Sarlauskas J, Jonusiene V, Maroziene A, Miseviciene L, Yantsevich A
Int J Mol Sci. 2019; 20(18).
PMID: 31533349
PMC: 6769651.
DOI: 10.3390/ijms20184602.
Hypoxia-activated prodrugs and (lack of) clinical progress: The need for hypoxia-based biomarker patient selection in phase III clinical trials.
Spiegelberg L, Houben R, Niemans R, De Ruysscher D, Yaromina A, Theys J
Clin Transl Radiat Oncol. 2019; 15:62-69.
PMID: 30734002
PMC: 6357685.
DOI: 10.1016/j.ctro.2019.01.005.
Radiotherapy Synergizes with the Hypoxia-Activated Prodrug Evofosfamide: In Vitro and In Vivo Studies.
Takakusagi Y, Kishimoto S, Naz S, Matsumoto S, Saito K, Hart C
Antioxid Redox Signal. 2017; 28(2):131-140.
PMID: 28741367
PMC: 5725636.
DOI: 10.1089/ars.2017.7106.
Crystal structure of N-(quinolin-6-yl)hydroxyl-amine.
Rajapakse A, Hillebrand R, Lewis S, Parsons Z, Barnes C, Gates K
Acta Crystallogr Sect E Struct Rep Online. 2014; 70(Pt 11):322-4.
PMID: 25484734
PMC: 4257318.
DOI: 10.1107/S160053681402193X.
Toward hypoxia-selective DNA-alkylating agents built by grafting nitrogen mustards onto the bioreductively activated, hypoxia-selective DNA-oxidizing agent 3-amino-1,2,4-benzotriazine 1,4-dioxide (tirapazamine).
Johnson K, Parsons Z, Barnes C, Gates K
J Org Chem. 2014; 79(16):7520-31.
PMID: 25029663
PMC: 4136725.
DOI: 10.1021/jo501252p.
Type 1 Phototherapeutic Agents. 2. Cancer Cell Viability and ESR Studies of Tricyclic Diarylamines.
Rajagopalan R, Lin T, Karwa A, Poreddy A, Asmelash B, Dorshow R
ACS Med Chem Lett. 2014; 3(4):284-8.
PMID: 24900465
PMC: 4025672.
DOI: 10.1021/ml200266v.
Type 1 phototherapeutic agents, part I: preparation and cancer cell viability studies of novel photolabile sulfenamides.
Karwa A, Poreddy A, Asmelash B, Lin T, Dorshow R, Rajagopalan R
ACS Med Chem Lett. 2014; 2(11):828-33.
PMID: 24900271
PMC: 4018100.
DOI: 10.1021/ml2001483.
Enzymatic conversion of 6-nitroquinoline to the fluorophore 6-aminoquinoline selectively under hypoxic conditions.
Rajapakse A, Linder C, Morrison R, Sarkar U, Leigh N, Barnes C
Chem Res Toxicol. 2013; 26(4):555-63.
PMID: 23488987
PMC: 4003570.
DOI: 10.1021/tx300483z.
Hypoxia-selective, enzymatic conversion of 6-nitroquinoline into a fluorescent helicene: pyrido[3,2-f]quinolino[6,5-c]cinnoline 3-oxide.
Rajapakse A, Gates K
J Org Chem. 2012; 77(7):3531-7.
PMID: 22417220
PMC: 3360953.
DOI: 10.1021/jo3004748.
Distinct roles of cytochrome P450 reductase in mitomycin C redox cycling and cytotoxicity.
Wang Y, Gray J, Mishin V, Heck D, Laskin D, Laskin J
Mol Cancer Ther. 2010; 9(6):1852-63.
PMID: 20501808
PMC: 3781016.
DOI: 10.1158/1535-7163.MCT-09-1098.